Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03059888 · ClinicalTrials.gov registry record · Early Phase 1
Trial of Orencia in Patients With Myasthenia Gravis
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT03059888: Clinical Trial Early Phase 1 study, sponsored by Johns Hopkins University.
NCT03059888 is a Early Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03059888, a Early Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This pilot research study is being done to see if the drug abatacept (Orencia ®) will be helpful in treating patients with myasthenia gravis (MG) who do not respond satisfactorily to other drugs that are used to suppress the immune system. Abatacept has been successful in treating experimental MG in laboratory animals, and this study is to determine its effectiveness in patients with MG.
Interventions
- DRUG Abatacept Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2019-07-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03059888
The ClinicalTrials.gov registry entry for NCT03059888 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abatacept Injection is the first listed.
NCT03059888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03059888 about?
NCT03059888 is a clinical study titled "Trial of Orencia in Patients With Myasthenia Gravis". This pilot research study is being done to see if the drug abatacept (Orencia ®) will be helpful in treating patients with myasthenia gravis (MG) who do not respond satisfactorily to other drugs that are used to suppress the immune system. Abatacept has been successful in treating experimental MG in...
What is the current status of trial NCT03059888?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2017-04-12. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT03059888?
The interventions under investigation include: Abatacept Injection (DRUG).
Who is sponsoring clinical trial NCT03059888?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.